antibody-based hiv-1 vaccines recent developments and future directions基于抗体的hiv - 1疫苗最近的进展和未来的发展方向.pdfVIP

Policy Forum Antibody-Based HIV-1 Vaccines: Recent Developments and Future Directions A summary report from a Global HIV Vaccine Enterprise Working Group * David Montefiori , Quentin Sattentau, Jorge Flores, José Esparza, John Mascola on behalf of a Working Group convened by the Global HIV Vaccine Enterprise he Global HIV Vaccine neutralization will predict protection Structure-Assisted Immunogen Enterprise convened a two-day in vaccine recipients, it is clear that Design Tworkshop in May of 2007 to current vaccine immunogens elicit Clinical studies have demonstrated that discuss humoral immune responses to antibodies that neutralize only a immunization with the gp120 surface HIV and approaches to design vaccines minority of circulating isolates. Thus, unit of the HIV-1 envelope protein that induce viral neutralizing and much progress needs to be made in this does not lead to the induction of other potentially protective antibody area. Also, though virus neutralization potent or broadly reactive neutralizing responses. The goals of this workshop is considered a critical benchmark antibodies. In order to develop better were to identify key scientific issues, for a vaccine, this may not be the only